Advanced search
Publication Cover
Acta Cardiologica Volume 76, 2021 - Issue 2
Submit an article Journal homepage
896
Views
3
CrossRef citations to date
0
Altmetric
View Points

Bail-out extracorporeal membrane oxygenation for hydroxychloroquine intoxication: a warning for COVID-19 health-care givers

Wouter Holvoeta Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, BelgiumCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7951-5239
ORCID Icon,
Kaja van Soestb Department of Clinical Pharmacy, Maastricht University Medical Center, Maastricht, The Netherlands
,
Thomas Havenithb Department of Clinical Pharmacy, Maastricht University Medical Center, Maastricht, The Netherlands
,
Roberto Lorussoc Department of Cardio-thoracic Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
,
Walther N. K. A. van Mookd Department of Intensive Care, Maastricht University Medical Center, Maastricht, The Netherlands
&
Thijs Delnoije Department of Intensive Care and Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands
Pages 200-203 | Received 24 Apr 2020, Accepted 26 Jul 2020, Published online: 14 Dec 2020

References

  • Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
  • Colson P, Rolain J-M, Lagier J-C, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
  • Hinton DM. Food and Drug Administration. FDA Emergency use authorization (EUA) of chloroquine and hydroxychloroquine. 28 Mar 2020. Available from: https://www.fda.gov/media/136534/download
  • Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036–1041.
  • Yanturali S, Aksay E, Demir OF, et al. Massive hydroxychloroquine overdose. Acta Anaesthesiol Scand. 2004;48(3):379–381.
  • Isbister GK, Dawson A, Whyte IM. Hydroxychloroquine overdose: a prospective case series. Am J Emerg Med. 2002;20(4):377–378.
  • Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med. 2001;19(5):420–424.
  • Mégarbane B, Bloch V, Hirt D, et al. Blood concentrations are better predictors of chloroquine poisoning severity than plasma concentrations: a prospective study with modelling of the concentration/effect relationships. Clin Toxicol. 2010;48(9):904–915.
  • Riou B, Barriot P, Rimailho A, et al. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318(1):1–6.
  • Ten Broeke R, Mestrom E, Woo L, et al. Early treatment with intravenous lipid emulsion in potentialy lethal hydroxychloroquine intoxication. Neth J Med. 2016;74(5):210–214.
  • Mongenot F, Tessier Gonthier Y, Derderian F, et al. Treatment of hydroxychloroquine poisoning with extracorporeal circulation. Ann Fr Anesth Reanim. 2007;26(2):164–167.
  • Weiner L, Mazzeffi MA, Hines EQ, et al. Clinical utility of venoarterial-extracorporeal membrane oxygenation (VA-ECMO) in patients with drug-induced cardiogenic shock: a retrospective study of the extracorporeal life support organizations' ECMO case registry. Clin Toxicol (Pila). 2020;58(7):705–710.
  • Masson R, Colas V, Parienti JJ, et al. A comparison of survival with and without extracorporeal life support treatment for severe poisoning due to drug intoxication. Resuscitation. 2012;83(11):1413–1417.
  • Pozzi M, Koffel C, Djaref C, et al. High rate of arterial complications in patients supported with extracorporeal life support for drug intoxication-induced refractory cardiogenic shock or cardiac arrest. J Thorac Dis. 2017;9(7):1988–1996.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.